“Cullinan is strategically focusing resources and development efforts on select, high-conviction clinical stage programs. We are well-positioned to further concentrate resources on CLN-978, a CD19xCD3 bispecific T cell engager, and we plan to share initial clinical data in autoimmune diseases in the first half of 2026. We are also particularly encouraged by the emerging efficacy profile of CLN-049, our FLT3xCD3 bispecific T cell engager, and we look forward to unveiling important clinical data in an oral presentation at the upcoming 2025 ASH Annual Meeting in December. We believe the differentiated mechanism of CLN-049 supports its potential to address a broad population of AML patients regardless of mutational status, including those with poor prognostic features,” said Nadim Ahmed, Chief Executive Officer of Cullinan Therapeutics (CGEM).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Promising Phase 1 Results for CLN-049 in AML Justify Buy Rating
- Cullinan Management Unveils Promising CLN-049 Clinical Data
- Cullinan Therapeutics to showcase new data from Phase 1 study of CLN-049
- Promising Clinical Trial Results and Strategic Partnerships Drive Buy Rating for Cullinan Management
- Buy Rating for Cullinan Management’s Zipalertinib: Promising Efficacy in Challenging EGFR Mutated NSCLC Cases